ABOUT this BLOG and How to use it

WELCOME to Stu's Views and MS News e-Newsletter Ô

Key-Note: Our live MS educational seminars average approx 65 people per educational program and SINCE our first program in February 2010, we have hosted more than 118 educational programs. Most locations are in Florida and we have now added educational events in Georgia, Alabama and the Carolinas.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.

Visit MS Views and News.org

Be Empowered with MS News and Information

Scroll to view All the resources found on the left side of this blog. Need to find information, use our 'search by topic' tool.


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Wednesday, September 30, 2009

EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States


  • Press Release
  • Source: EMD Serono, Inc. - On Wednesday September 30, 2009


ROCKLAND, Mass., Sept. 30 /PRNewswire/ -- EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies.

"As a leader in the area of neurodegenerative diseases, we continue to focus on making a positive difference in the lives of people living with MS, and their families," said Fereydoun Firouz, President and CEO of EMD Serono, Inc. "If approved, short-course therapy with Cladribine Tablets could transform the way people approach their treatment options, and meet an unmet need as an oral, disease modifying drug available for MS. We look forward to working with the FDA during the course of the regulatory process."

Continue reading this article on oral cladribine by clicking here

Remain up-to-date with MS news and receive our weekly MS related e-newsletter, published each Thursday.
Click here to register - to receive Stu's Views and M.S. Related News.

..............................................................................................

No comments: